According to the Zhitong Finance App, Maike Pharmaceutical-B (02335.HK) announced that the company and Beijing Tiantan Hospital (Beijing Tiantan Hospital) affiliated to Capital Medical University jointly undertook a research project involving the company's key product MT200605 under the “Major New Drug Creation” national science and technology project, and has recently received the first special funding from the central government for this project. The company has also obtained ethical approval from the MT200605 phase III clinical trial team leader unit.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.